Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis

A method for treating epileptogenesis, comprising administering to a patient in need of treatment with an anti-epileptogenic drug (an AEGD) a therapeutically effective amount of a compound of formula (I)

• wherein
• R1 is selected from the group consisting of hydrogen, halogen, hydroxy, methoxy, trifluoromethyl, nitro and cyano;
• X—Y is selected from the group consisting of —S—CH—, —S—C(CH3)—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;
• A is selected from the group consisting of —CH2— and —CH(CH3)—;
• R2 is selected from the group consisting of hydrogen and methyl;
• R3 and R4 are each independently selected from the group consisting of hydrogen and C1-4alkyl;
• alternatively, R3 and R4 are taken together with the nitrogen atom to which they are bound to form a 5 to 7 membered, saturated, partially unsaturated or aromatic ring structure, optionally containing one to two additional heteroatoms independently selected from the group consisting of O, N and S;
• or a pharmaceutically acceptable salt thereof.